- Home
- CLPR vs GUTS Comparison
CLPR vs GUTS Comparison
Compare CLPR & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPR
- GUTS
- Stock Information
- Founded
- CLPR 2015
- GUTS 2010
- Country
- CLPR United States
- GUTS United States
- Employees
- CLPR N/A
- GUTS N/A
- Industry
- CLPR Real Estate Investment Trusts
- GUTS
- Sector
- CLPR Real Estate
- GUTS
- Exchange
- CLPR Nasdaq
- GUTS NYSE
- Market Cap
- CLPR 57.8M
- GUTS 58.8M
- IPO Year
- CLPR 2017
- GUTS 2024
- Fundamental
- Price
- CLPR $3.57
- GUTS $1.49
- Analyst Decision
- CLPR
- GUTS Buy
- Analyst Count
- CLPR 0
- GUTS 1
- Target Price
- CLPR N/A
- GUTS $10.00
- AVG Volume (30 Days)
- CLPR 89.5K
- GUTS 936.1K
- Earning Date
- CLPR 07-31-2025
- GUTS 08-13-2025
- Dividend Yield
- CLPR 10.64%
- GUTS N/A
- EPS Growth
- CLPR N/A
- GUTS N/A
- EPS
- CLPR N/A
- GUTS N/A
- Revenue
- CLPR $152,413,000.00
- GUTS $60,000.00
- Revenue This Year
- CLPR N/A
- GUTS N/A
- Revenue Next Year
- CLPR N/A
- GUTS N/A
- P/E Ratio
- CLPR N/A
- GUTS N/A
- Revenue Growth
- CLPR 8.63
- GUTS N/A
- 52 Week Low
- CLPR $3.38
- GUTS $0.87
- 52 Week High
- CLPR $7.12
- GUTS $4.92
- Technical
- Relative Strength Index (RSI)
- CLPR 39.88
- GUTS 41.13
- Support Level
- CLPR $3.65
- GUTS $1.47
- Resistance Level
- CLPR $3.94
- GUTS $1.68
- Average True Range (ATR)
- CLPR 0.16
- GUTS 0.15
- MACD
- CLPR -0.02
- GUTS -0.05
- Stochastic Oscillator
- CLPR 0.00
- GUTS 5.88
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.